SUNNYVALE, Calif., Oct. 8 /PRNewswire-FirstCall/ --
Scios Inc. (Nasdaq: SCIO) today announced that four abstracts related to
Natrecor(R) (nesiritide) were presented at the American College of Emergency
Physicians (ACEP) Scientific Assembly 2002 in Seattle, the world's largest and
most comprehensive emergency medicine educational conference.
"Since most patients with acutely decompensated heart failure present to
the Emergency Department, it is important that ACEP physicians from around the
country have the opportunity to advance their understanding of Natrecor as an
early treatment strategy in the Emergency Department," said Darlene P. Horton,
M.D., Vice President of Medical Affairs at Scios.
One of the presentation highlights was titled, "Effect of Emergency
Department Initiation of Vasoactive Infusion Therapy on Heart Failure Length
of Stay," presented by Charles L. Emerman M.D., and W. Franklin Peacock IV,
M.D., both of the Department of Emergency Medicine, The Cleveland Clinic
Foundation. The abstract concluded, "initiation of IV vasoactive infusion
therapy in the Emergency Department (ED) rather than on the inpatient unit is
associated with a markedly shorter hospital length of stay (LOS) in patients
presenting with acutely decompensated heart failure." The analysis was based
on data from the ADHERE registry, a national multicenter registry that enrolls
acutely decompensated heart failure patients.
Treatment was categorized as those receiving only first-line, intermittent
ED heart failure therapy such as diuretics, morphine and other bolus IV
agents, versus those receiving IV vasoactive infusion therapies such as IV
vasodilators, Natrecor (nesiritide) or inotropes initiated in the ED. A key
finding of the study was that the length of stay for patients who received IV
vasoactive infusion therapy in the ED was 6.4 days vs. 9.5 days for those who
started this therapy after admission (P<0.001).
"It is critical that emergency physicians recognize the need for
aggressive initial treatment of patients with acutely decompensated heart
failure with IV vasoactive infusion therapies like Natrecor in the Emergency
Department since these drugs favorably impact clinical outcomes such as
hospital length of stay," said Charles L. Emerman, M.D., Department of
Emergency Medicine, The Cleveland Clinic Foundation.
Additional studies presented at the ACEP meeting included:
-- Efficacy and Safety of Nesiritide (B-type natriuretic peptide) vs.
Intravenous Nitroglycerin in Patients with Renal Insufficiency, Charles
L. Emerman, M.D. et al, Department of Emergency Medicine, The Cleveland
Clinic Foundation.
-- Safety of Nesiritide During Infusion for Decompensated Heart Failure,
W. Franklin Peacock IV, M.D. et al, Department of Emergency Medicine,
The Cleveland Clinic Foundation.
-- A Pilot Study of the Safety and Efficacy of Nesiritide in the
Management of Acute Decompensated Congestive Heart Failure Complicated
by an Acute Coronary Syndrome, W. Franklin Peacock IV, M.D. et al,
Department of Emergency Medicine, The Cleveland Clinic Foundation.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for
cardiovascular and inflammatory disease. The Company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
Forward-Looking Safe Harbor Statement
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We generally identify such forward-looking statements
using words like "estimate," "believe," "intend," "expect," "may," "should,"
"plan," "project," "contemplate," "anticipate" or similar statements.
Statements that are not historical facts are forward-looking statements based
on current assumptions that involve risks and uncertainties. These risks and
uncertainties may include the sales penetration and success of Natrecor, the
success of clinical trials of Natrecor and our pipeline products, including
SCIO-469 and inhibitors to TGF-beta, our ability to partner the development
and commercialization of our pipeline products and Natrecor (outside the U.S.
and Europe) with third parties on favorable terms, or at all, as well as other
risks detailed from time to time in the reports filed by Scios with the SEC,
including the Company's quarterly reports and annual report on Form 10-K.
Actual results, performance or achievements of Scios may differ significantly
from those described in these forward-looking statements. Scios disclaims any
intention or obligation to update or revise any financial projections or
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
media and investors, Suzanne Beveridge of
Scios Inc., +1-408-616-2947; or media, Jim Weiss of WeissCom
Partners, Inc., +1-415-260-1274; or investors, Fern Lazar or Sara
Moorin of Lazar Partners Ltd., +1-212-867-1762, for Scios Inc.
|
